MannKind Corp

MNKD

Market cap $952M

Investors weren't pleased with the biotech's bottom-line decline. It also missed the consensus analyst estimate for that metric.

MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

MannKind (MNKD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.

Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is scheduled to present and share business updates during the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 11:20 a.m. ET

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind Corporation is transitioning from a volatile biotech to a diversified, revenue-driven pharma, with FUROSCIX and Afrezza driving commercial momentum. MNKD's 2026 business outlook highlights expanding commercial assets, key regulatory milestones, and a strong pipeline, positioning 2026 as a potential breakout year. Afrezza's FDA label update removes adoption barriers, expanding its addressable market and supporting MNKD's long-term growth thesis.

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin